Bin Yu1, Youming Ding2, Xiaofeng Liao3, Changhua Wang4, Bin Wang1, Xiaoyan Chen1. 1. Department of Hepatobiliary and Laparoscopic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, People's Republic of China. 2. Department of Hepatobiliary and Laparoscopic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, People's Republic of China. dingym@whu.edu.cn. 3. Department of General Surgery, Xiangyang Central Hospital, Xiangyang, 441021, Hubei Province, People's Republic of China. 4. Department of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071, Hubei Province, People's Republic of China.
Abstract
BACKGROUND: PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer. OBJECTIVE: To investigate the expression profile of PARPBP and its role in hepatocellular carcinoma (HCC). METHODS: Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test. The prognostic value of PARPBP in HCC was evaluated by Kaplan-Meier method, Cox regression analysis, and nomogram. Gene set enrichment analysis (GSEA) was used to screen biological pathways correlated with PARPBP expression in HCC. RESULTS: PARPBP was significantly upregulated in HCC tissues compared with normal liver tissues (P < 0.05). High PARPBP expression was significantly associated with elevated serum AFP level, vascular invasion, poor tumor differentiation, and advanced TNM stage (all P < 0.05). Kaplan-Meier analyses suggested that upregulation of PARPBP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC. Multivariate analyses further confirmed that PARPBP upregulation was an independent indicator of poor OS and RFS (all P < 0.05). The prognostic nomograms based on PARPBP mRNA expression and TNM stage were superior to those based on the TNM staging system alone (all P < 0.05). Besides, PARPBP DNA copy gain and miR-139-5p downregulation were associated with PARPBP upregulation in HCC. GSEA revealed that "cell cycle," "HR," "DNA replication," and "p53 signaling" pathways were enriched in high PARPBP expression group. CONCLUSION: PARPBP may be a promising prognostic biomarker and candidate therapeutic target in HCC.
BACKGROUND:PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer. OBJECTIVE: To investigate the expression profile of PARPBP and its role in hepatocellular carcinoma (HCC). METHODS: Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test. The prognostic value of PARPBP in HCC was evaluated by Kaplan-Meier method, Cox regression analysis, and nomogram. Gene set enrichment analysis (GSEA) was used to screen biological pathways correlated with PARPBP expression in HCC. RESULTS:PARPBP was significantly upregulated in HCC tissues compared with normal liver tissues (P < 0.05). High PARPBP expression was significantly associated with elevated serum AFP level, vascular invasion, poor tumor differentiation, and advanced TNM stage (all P < 0.05). Kaplan-Meier analyses suggested that upregulation of PARPBP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC. Multivariate analyses further confirmed that PARPBP upregulation was an independent indicator of poor OS and RFS (all P < 0.05). The prognostic nomograms based on PARPBP mRNA expression and TNM stage were superior to those based on the TNM staging system alone (all P < 0.05). Besides, PARPBP DNA copy gain and miR-139-5p downregulation were associated with PARPBP upregulation in HCC. GSEA revealed that "cell cycle," "HR," "DNA replication," and "p53 signaling" pathways were enriched in high PARPBP expression group. CONCLUSION:PARPBP may be a promising prognostic biomarker and candidate therapeutic target in HCC.
Authors: Mathias Uhlen; Per Oksvold; Linn Fagerberg; Emma Lundberg; Kalle Jonasson; Mattias Forsberg; Martin Zwahlen; Caroline Kampf; Kenneth Wester; Sophia Hober; Henrik Wernerus; Lisa Björling; Fredrik Ponten Journal: Nat Biotechnol Date: 2010-12 Impact factor: 54.908
Authors: J Ma; M Gao; Y Lu; X Feng; J Zhang; D Lin; T Xiao; Z Hu; J Yuan; K Su; J Shipley; J Xue; Y Gao Journal: J Pathol Date: 2006-10 Impact factor: 7.996
Authors: Marcus Alvarez; Jihane N Benhammou; Nicholas Darci-Maher; Samuel W French; Steven B Han; Janet S Sinsheimer; Vatche G Agopian; Joseph R Pisegna; Päivi Pajukanta Journal: Genome Med Date: 2022-05-17 Impact factor: 15.266
Authors: Shikshya Shrestha; Anthony Lamattina; Gustavo Pacheco-Rodriguez; Julie Ng; Xiaoli Liu; Abhijeet Sonawane; Jewel Imani; Weiliang Qiu; Kosmas Kosmas; Pierce Louis; Anne Hentschel; Wendy K Steagall; Rieko Onishi; Helen Christou; Elizabeth P Henske; Kimberly Glass; Mark A Perrella; Joel Moss; Kelan Tantisira; Souheil El-Chemaly Journal: Life Sci Alliance Date: 2022-02-18